Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Streptococcus mutans ±Õ¿¡ ÀÇÇØ Çü¼ºµÈ ¹ÙÀÌ¿ÀÇʸ§¿¡ ´ëÇÑ Glycyrrhetinic acidÀÇ ºÒ¾ÈÁ¤È­ È¿°ú

Destabilizing effect of glycyrrhetinic acid on pre-formed biofilms of Streptococcus mutans

´ëÇѱ¸°­º¸°ÇÇÐȸÁö 2016³â 40±Ç 1È£ p.38 ~ 42
À¯Á¤Çå, ÀÌ´Ù¹Ì, ÀÌ»óÈ­,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯Á¤Çå ( Yu Jung-Heon ) - LG»ýÈ°°Ç°­ ±â¼ú¿¬±¸¿ø
À̴ٹ̠( Lee Da-Mi ) - LG»ýÈ°°Ç°­ ±â¼ú¿¬±¸¿ø
ÀÌ»óÈ­ ( Lee Sang-Hwa ) - LG»ýÈ°°Ç°­ ±â¼ú¿¬±¸¿ø

Abstract


Objectives: In this study, the destabilizing effect of glycyrrhetinic acid on pre-formed biofilms of Strepto-coccus mutans (S. mutans) was observed.

Methods: Alamar blue assay was used to determine the toxicity of glycyrrhetinic acid on pre-formed biofilms of S. mutans. Four different concentrations (0, 3.75, 7.5, 15 ¥ìg/ml) of glycyrrhetinic acid were tested. Changes in the biofilm architecture after exposure to glycyrrhetinic acid were analyzed by scan-ning electron microscopy (SEM). Moreover, the role of glycyrrhetinic acid in enhancing the antimicrobial activity of cetylpyridinium chloride (CPC), an antimicrobial agent commonly used in oral health care products, was evaluated.

Results: Glycyrrhetinic acid concentration of up to 15 ¥ìg/ml had little cytotoxic effect but significantly changed the biofilm architecture. SEM analysis revealed destabilized biofilm structure after the pre-formed biofilms were exposed to glycyrrhetinic acid. Supplementing 2.5 ¥ìg/ml CPC with 15 ¥ìg/ml glycyrrhetinic acid significantly enhanced the bactericidal effect of CPC on the pre-formed biofilms than that in the non-supplemented CPC treated control. This indicates that glycyrrhetinic acid enhanced the antimicrobial activity of CPC by modifying the structure, thus facilitating the penetration of CPC into the biofilm.

Conclusions: Glycyrrhetinic acid could be a potential agent to effectively control S. mutans biofilms re-sponsible for dental caries.

Å°¿öµå

Biofilm destabilizing effect; Dental caries; Glycyrrhetinic acid; Streptococcus mutans

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed